ArticleFrontiers in oncology2020

MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer.

Ah-Young Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.